Nasdaq

Business

Tower Semiconductor Bets Big on AI and Photonics with $650M Expansion Amid Soaring Valuation Questions

Tower Semiconductor (TSEM) has captured market attention with record revenue guidance and a major $650 million capacity expansion targeting silicon photonics and SiGe technologies. While shares have surged over 58% in 90 days, analysts are now debating whether the stock's premium valuation fully prices in future growth in AI, 5G, and data center markets.

Jan 30, 2026

Business

Intuitive Machines Bolsters Space Ambitions with $800M Lanteris Acquisition and NASA Artemis II Role

Intuitive Machines (LUNR) is set to acquire Lanteris Space Systems in an $800 million deal, expanding its capabilities into vertically integrated space infrastructure. Concurrently, NASA has selected the company to provide critical tracking support for the upcoming Artemis II crewed lunar mission, signaling growing trust in its technical prowess.

Jan 30, 2026

Business

Pool Corp's Stock: A Turnaround in Momentum or a Value Trap?

After a challenging year, Pool Corp's shares have shown a notable uptick over the past month, reigniting the debate over its valuation. With a significant gap between its current price and analyst targets, investors are weighing short-term momentum against longer-term headwinds in the housing and outdoor living sectors.

Jan 30, 2026

Business

Korro Bio Unveils RNA-Editing Therapy KRRO-121, Aiming to Redefine Ammonia Control for Rare Metabolic and Liver Disorders

At its Analyst Day, Korro Bio detailed its lead candidate KRRO-121, an RNA-editing therapeutic designed to tackle hyperammonemia in urea cycle disorders and hepatic encephalopathy by stabilizing a key liver enzyme, positioning it as a potential paradigm shift from current burdensome treatments.

Jan 30, 2026

Business

Beyond Nvidia: Two AI Infrastructure Giants Poised for Growth as Tech Titans Ramp Up Spending

With hyperscalers projected to pour $500 billion into AI infrastructure by 2026, investors are looking beyond headline chipmakers to the essential, yet often overlooked, backbone providers of the AI revolution.

Jan 30, 2026

Business

AI Infrastructure Showdown: Can IREN and APLD Sustain Their Meteoric Rise?

Once crypto miners, IREN and Applied Digital have pivoted to AI infrastructure, delivering staggering returns. But as valuations soar, investors face a critical choice between predictable cash flow and high-growth optionality.

Jan 30, 2026

Business

Peloton's Pivot: From Pandemic Darling to a Fight for Fitness Market Relevance

Once the undisputed leader in connected fitness, Peloton Interactive is navigating a critical business reset. Faced with declining revenue, subscriber churn, and a shifting market, the company is trading rapid expansion for a strategy focused on cost control and stabilization. The core question for investors is whether its brand and ecosystem can sustain a profitable future.

Jan 30, 2026

Business

Cisco Bets Big on Polish Solar, Signaling Strategic Shift in European Energy and ESG Leadership

Cisco Systems has inked a major 15-year virtual power purchase agreement for solar energy in Poland, a move that extends its environmental commitments into one of Europe's more fossil-fuel-dependent grids and underscores its long-term capital allocation strategy beyond core tech.

Jan 30, 2026

Business

AMD and GIGABYTE Forge Deeper AI Alliance, Targeting the Next Wave of Gaming PCs

AMD and GIGABYTE have significantly expanded their partnership to co-develop a new generation of AI-accelerated gaming laptops, motherboards, and monitors. This strategic move aims to bring powerful, on-device AI capabilities directly to consumers, potentially reshaping competitive dynamics in the PC gaming hardware market.

Jan 30, 2026

Business

BofA Doubles Down on Hesai Group, Boosts Price Target on Lidar Leadership and Regulatory Tailwinds

Bank of America Securities has reaffirmed its Buy rating on Hesai Group (HSAI), raising its price target to $32, citing the lidar maker's technological milestones, strategic partnership with NVIDIA, and favorable regulatory developments for autonomous driving.

Jan 30, 2026

Business

Atour Emerges as a Premium Contender in China's Hotel Wars, Says CLSA

Brokerage firm CLSA initiates coverage on Atour Lifestyle Holdings with an 'Outperform' rating and a $49 price target, highlighting its unique brand ecosystem and asset-light model as key differentiators in a competitive market.

Jan 30, 2026

Business

Regulatory Headwinds Cloud Outlook for PDD Holdings Amid Broader China Internet Crackdown

While Morgan Stanley maintains an Overweight rating on PDD Holdings, the firm has removed the e-commerce giant from its Top Picks list, citing heightened regulatory scrutiny and a slower-than-expected consumer recovery in China.

Jan 30, 2026

Business

Genmab Shares Face Target Cut After EPKINLY Trial Misses Survival Goal, But Analysts Keep Faith

H.C. Wainwright has trimmed its price target on Genmab following mixed Phase 3 results for its lymphoma drug EPKINLY, though maintains a Buy rating, citing precedent and ongoing trials.

Jan 30, 2026

Business

Analysts Bullish on BeOne Medicines: Phase 3 Success Fuels $3.8B Revenue Forecast for 2025

Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.

Jan 30, 2026

Business

RBC Lifts Price Target on Ascendis Pharma, Backs Growth Trajectory Through 2026

RBC Capital has reaffirmed its confidence in Ascendis Pharma, raising its price target following the company's ambitious 2026 strategic goals, which hinge on sustained momentum for its lead therapy and significant long-term revenue targets.

Jan 30, 2026

Business

Argenx's Vyvgart Surges Past Sales Forecasts, Fueling Optimism for Autoimmune Portfolio

Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.

Jan 30, 2026

Business

Tesla Shifts Gears: Fremont Factory Retooled for Optimus Robots as $2 Billion Bet on xAI Fuels AI Ambitions

Tesla is pivoting its core strategy, phasing out legacy Model S and X production to mass-manufacture Optimus humanoid robots and deepening its commitment to artificial intelligence with a major investment in Elon Musk's xAI. This strategic realignment signals a future where the company's identity may evolve from electric vehicle pioneer to a broader AI and robotics powerhouse.

Jan 30, 2026

Business

AbCellera Biologics: A Tale of Two Valuations Amid Steep Share Decline

Shares of antibody discovery firm AbCellera Biologics plunged 16.8% last week, reigniting debate over its true worth. While a discounted cash flow model suggests deep undervaluation, its sky-high price-to-sales ratio paints a starkly different picture, leaving investors to navigate conflicting signals in a volatile biotech market.

Jan 30, 2026

Business

Fractyl Health Charts Path for Revita as Potential Solution to Post-GLP-1 Weight Regain

Fractyl Health's Revita procedure shows promise in maintaining weight after stopping GLP-1 drugs, with new six-month data prompting the company to seek a streamlined FDA pathway. A packed 2026 roadmap aims for a U.S. submission, but financial pressures loom.

Jan 30, 2026

Business

Plains All American Doubles Down on Crude with EPIC Pipeline Deal, Sparking Investor Debate

Plains All American Pipeline's strategic pivot—selling its Canadian NGL unit for $3.8 billion to fund the acquisition of the EPIC Crude Oil Pipeline—has sharpened its focus on oil transportation. While a 10% distribution hike signals confidence, analyst downgrades and heightened options volatility ahead of earnings reveal deep divisions over the company's risk-reward profile.

Jan 30, 2026